Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Premature Ejaculation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Ejaculation - Companies Involved in Therapeutics Development
Ctcbio Inc
Dicot AB
Ixchelsis Ltd
NeuroHealing Pharmaceuticals Inc
Plethora Solutions Holdings Plc
Premature Ejaculation - Drug Profiles
(clomipramine hydrochloride + sildefil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cligosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Sep 19, 2019: Plethora Pharma Solutions receives CHMP positive opinion for Senstend
Jul 11, 2018: Dicot signs extended Service Agreement with Anthem Biosciences for Preclinical Development of Libiguin
Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
Nov 11, 2014: Plethora Solutions Provides Company Update
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
Mar 11, 2014: Plethora Solutions Provides Company update
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
Dec 19, 2011: Plethora Provides Update On PSD502
Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Premature Ejaculation, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Premature Ejaculation, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Premature Ejaculation - Pipeline by Ctcbio Inc, H1 2020
Premature Ejaculation - Pipeline by Dicot AB, H1 2020
Premature Ejaculation - Pipeline by Ixchelsis Ltd, H1 2020
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2020
Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H1 2020
Premature Ejaculation - Dormant Projects, H1 2020
Premature Ejaculation - Discontinued Products, H1 2020